Jounce Therapeutics, Inc.
Jounce Therapeutics, Inc. (JNCE) is a publicly traded company in the Unknown sector. Across all available filings, 18 corporate insiders have executed 156 transactions totaling $42.7M, demonstrating a bearish sentiment with -$42.5M in net insider flow. The most recent transaction on May 3, 2023 involved a transaction of 25,751 shares valued at $0.
JNCE Insider Activity Summary
Who Is Buying JNCE Stock?
No significant insider buying has been recorded for JNCE in the recent period.
Who Is Selling JNCE Stock?
No significant insider selling has been recorded for JNCE in the recent period.
Is Jounce Therapeutics, Inc. Insider Trading Bullish or Bearish?
Based on recent SEC filings, insider sentiment for JNCE is bearish with an Insider Alignment Score of 0/100 and a net flow of -$42.5M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
JNCE Frequently Asked Questions
Understanding JNCE Insider Activity
Insider trading at Jounce Therapeutics, Inc. (JNCE) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 18 insiders are actively trading JNCE stock, having executed 156 transactions in the past 90 days. The most active insider is Kevin C. Tang (Executive), who has made 2 transactions totaling $107.2M.
Related Tools
Track Jounce Therapeutics, Inc. Insider Activity
Get notified when executives and directors at JNCE file new Form 4 transactions